In this webinar, Dr. Scott Q. Siler, Chief Science Officer of QSP, discusses how quantitative systems pharmacology can help improve the efficiency of obesity drug development. Using the OBESITYsym model, Dr. Siler demonstrates how QSP can simultaneously predict weight loss and nausea outcomes for treatments in a simulated population of patients with obesity. The session also highlights recent model expansions, including oral obesity drugs such as semaglutide and orforglipron, as well as emerging therapies with additional mechanisms of action, such as the GLP-1/GIP/GLP triple agonist retatrutide. Viewers will get a first look at how these updates can provide a competitive edge in a rapidly growing and highly competitive obesity treatment market. Watch to learn how QSP can support smarter, more efficient clinical development strategies for obesity drugs.